Background: We aimed to find the potential beneficial effects of metoprolol, which was added to the treatment of COVID-19 patients with drug-induced long corrected QT (di-LQTc) interval. Materials and Methods: This study was a retrospective study. Hospitalized patient files were scanned, and the data of 160 Covid-19 positive patients who were confirmed by real-time polymerase chain reaction (RT-PCR) between April 1 and June 1, 2020, were analyzed. A total of 52 patients’ data with CoVID-19 patients with di-LQTc were scanned and collected in the metoprolol group, and a total of 108 patients’ data with CoVID-19 with normal QTc levels were collected in the non-metoprolol group. Results: The mean age was 48.58±16.52 (48.75% male). The in-hospital mortality rate was 3.125% (n=5). We did not see any malignant arrhythmias in the groups during follow-up. In the metoprolol group, the peak Qtc was 466.50 (458.75-477.50) msec in patients before metoprolol treatment, whereas it decreased to 443 (428.75-453) msec at discharge. Forward conditional logistic regression analysis demonstrated that basal C-reactive protein (CRP) (OR=1.031, 95%CI: 1.001-1.062, p=0.043) was the independent predictor of di-LQTc in Covid-19 patients. Conclusion: COVID-19 patients with di-LQTc could be treated and we thought we could reverse the QT prolongation by adding metoprolol to the treatment protocol.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.